An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

被引：0
|
作者：
Li, Bing [1 ,2 ]
Yin, Qing-song [2 ,3 ]
Yan, Xiaojing [3 ,4 ]
Hang, Min [5 ]
Guo, Hai-Jun [5 ]
Wang, Sheng [5 ]
Wang, Yi-wei [5 ]
Hei, Yong-jiang [5 ]
Xiao, Zhi-jian [1 ,2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, MDS & MPN Ctr, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Blood, Tianjin, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[4] China Med Univ, Hosp 1, Dept Hematol, Shenyang, Liaoning, Peoples R China
[5] Biocity Biopharmaceut Co Ltd, Wuxi, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201319
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4135 / 4136
页数：2
相关论文
共 50 条
  • [1] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [2] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [3] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
    Sekeres, Mikkael A.
    Schuster, Michael W.
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [4] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
    Zeidan, Amer Methqal
    Schuster, Michael
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Wendy
    Zeremski, Mirjana
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Savona, M. R.
    Garcia-Manero, G.
    Roboz, G. J.
    Walsh, K. J.
    Kropf, P. L.
    Issa, J. P.
    O'Connell, C. L.
    Tibes, R.
    Yee, K. W. L.
    Stock, W.
    Lunin, S.
    Berdeja, J. G.
    Naim, S.
    Hao, Y.
    Azab, M.
    Kantarjian, H.
    LEUKEMIA RESEARCH, 2017, 55 : S40 - S41
  • [6] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [7] A PHASE4, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE IN TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Laille, E.
    Chou, W.
    Yeh, S.
    Dong, Q.
    Songer, S.
    Beach, C.
    HAEMATOLOGICA, 2013, 98 : 577 - 578
  • [8] A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2014, 124 (21)
  • [9] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [10] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
    Giagounidis, A.
    Ades, L.
    Watts, J.
    Radinoff, A.
    Arnan Sangerman, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Bell, J.
    Friedlander, S.
    Faller, D. V.
    Sekeres, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
12345